Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian HIV PrEP/PEP 2025
Source-attributed clinical priorities
- Assess exposure type, source likelihood, timing, baseline HIV status and hepatitis and pregnancy considerations immediately.
- Start post-exposure prophylaxis as soon as indicated without waiting for all results, using the current provincial regimen.
- Complete interaction review, adherence support and scheduled HIV, renal, hepatic and STI follow-up.
- Post-exposure prophylaxis is time critical and should start as soon as possible within the Canadian eligibility window.
sources for this section:Canadian HIV PrEP/PEP 2025
Practical assessment and management workflow
1
Document exposure time, body fluid, route, source information, pregnancy and baseline medicines.
2
Perform baseline HIV, hepatitis and STI testing without delaying the first dose when indicated.
3
Select a recommended regimen after renal, liver and interaction review and arrange the full course.
4
Provide adherence support and scheduled repeat HIV and STI testing.
sources for this section:Canadian HIV PrEP/PEP 2025
Safety, red flags and urgent escalation
- Exposure older than the recommended window still requires testing, counselling and PrEP assessment.
- If the source is known HIV-positive, obtain urgent specialist information on viral load and resistance without delaying PEP.
- New symptoms during follow-up require reassessment for acute HIV or medication toxicity.
sources for this section:Canadian HIV PrEP/PEP 2025
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian HIV PrEP/PEP 2025
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian HIV PrEP/PEP 2025
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- CIHR Pan-Canadian Network for HIV/AIDS and STBBI Clinical Trials ResearchCanadian guideline on HIV pre- and postexposure prophylaxis: 2025 updateaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.